JAMA Otolaryngology–Head & Neck Surgery —The Year in Review, 2025
-
By
-
Jay F. Piccirillo
-
May 1, 2026
-
Clinical Scorecard: Annual Review of JAMA Otolaryngology–Head & Neck Surgery: Highlights from 2025
At a Glance
| Category | Detail |
| Condition | |
| Key Mechanisms | |
| Target Population | Children with DFNB9, patients with locally advanced head and neck squamous cell carcinoma, patients with thyroid diseases (specify types). |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- D
- e
- t
- a
- i
- l
-
- s
- p
- e
- c
- i
- f
- i
- c
-
- t
- o
- o
- l
- s
-
- o
- r
-
- m
- e
- t
- h
- o
- d
- o
- l
- o
- g
- i
- e
- s
-
- f
- o
- r
-
- p
- r
- e
- d
- i
- c
- t
- i
- n
- g
-
- t
- r
- e
- a
- t
- m
- e
- n
- t
-
- r
- e
- s
- p
- o
- n
- s
- e
- .
Risks
Patient & Prescribing Data
Patients with hereditary hearing loss, head and neck cancer, thyroid disease
Gene therapy and immune checkpoint inhibitors are emerging treatment options.
Clinical Best Practices
Related Resources & Content